Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10

Journal of Biological Chemistry

Volumn 289, Issue 32, 2014, Pages 22140-22150

  Sommer, Jan ^a   Garbers, Christoph ^b   Wolf, Janina ^b   Trad, Ahmad ^b   Moll, Jens M ^a   Sack, Markus ^c   Fischer, Rainer ^c   Grötzinger, Joachim ^b   Waetzig, Georg H ^d   Floss, Doreen M ^a   Scheller, Jürgen ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d CONARIS Research Institute AG ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SIGNALING;

CYTOKINES; INTERLEUKIN-6; ISOFORMS; NATURALLY OCCURRING; POLYADENYLATION;

IMMUNOLOGY;

AGENTS AFFECTING PROTEIN METABOLISM; COMPLEMENTARY DNA; GENOMIC DNA; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RECOMBINANT PROTEIN; SOLUBLE GP130 E10; SOLUBLE GP130 E10 FC PROTEIN; SOLUBLE GP130 FC PROTEIN; SOLUBLE INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; HYBRID PROTEIN; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; ISOPROTEIN; MULTIPROTEIN COMPLEX;

ALTERNATIVE INTRONIC POLYADENYLATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; GENE AMPLIFICATION; GENETIC CONSERVATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GP130 GENE; HALF LIFE TIME; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; INTRON; JURKAT CELL LINE; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR STABILITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TRANS SIGNALING INHIBITION; ALTERNATIVE RNA SPLICING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; METABOLISM; SIGNAL TRANSDUCTION; SOLUBILITY;

ALTERNATIVE SPLICING; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINE RECEPTOR GP130; HEK293 CELLS; HUMANS; INTERLEUKIN-6; INTRONS; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; POLYADENYLATION; PROTEIN ISOFORMS; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 84905842676     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.560938     Document Type: Article

References (27)

1. Jostock, T., Müllberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., and Rose-John, S. (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160-167
2. Jones, S. A., Scheller, J., and Rose-John, S. (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383
3. Waetzig, G. H., and Rose-John, S. (2012) Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin. Ther. Targets 16, 225-236
4. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G. D., Taga, T., and Kishimoto, T. (1993) Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membraneanchored gp130. Blood 82, 1120-1126
5. Tanaka, M., Kishimura, M., Ozaki, S., Osakada, F., Hashimoto, H., Okubo, M., Murakami, M., and Nakao, K. (2000) Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J. Clin. Invest. 106, 137-144
6. Zhang, J. G., Zhang, Y., Owczarek, C. M., Ward, L. D., Moritz, R. L., Simpson, R. J., Yasukawa, K., and Nicola, N. A. (1998) Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor-chain in normal human urine and plasma. J. Biol. Chem. 273, 10798-10805
7. Sharkey, A. M., Dellow, K., Blayney, M., Macnamee, M., Charnock-Jones, S., and Smith, S. K. (1995) Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Biol. Reprod. 53, 974-981
8. Diamant, M., Rieneck, K., Mechti, N., Zhang, X. G., Svenson, M., Bendtzen, K., and Klein, B. (1997) Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. 412, 379-384
9. Tian, B., Pan, Z., and Lee, J. Y. (2007) Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing. Genome Res. 17, 156-165
10. Vorlová, S., Rocco, G., Lefave, C. V., Jodelka, F. M., Hess, K., Hastings, M. L., Henke, E., and Cartegni, L. (2011) Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol. Cell 43, 927-939
11. Sommer, J., Effenberger, T., Volpi, E., Waetzig, G. H., Bernhardt, M., Suthaus, J., Garbers, C., Rose-John, S., Floss, D. M., and Scheller, J. (2012) Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J. Biol. Chem. 287, 13743-13751
12. Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J. P., Kallen, K. J., Wollmer, A., Grötzinger, J., and Rose-John, S. (1997) I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142-145
13. Schroers, A., Hecht, O., Kallen, K. J., Pachta, M., Rose-John, S., and Grötzinger, J. (2005) Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci. 14, 783-790
14. Floss, D. M., Mrotzek, S., Klöcker, T., Schröder, J., Grötzinger, J., Rose-John, S., and Scheller, J. (2013) Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor. J. Biol. Chem. 288, 19386-19400
15. Tenhumberg, S., Waetzig, G. H., Chalaris, A., Rabe, B., Seegert, D., Scheller, J., Rose-John, S., and Grötzinger, J. (2008) Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J. Biol. Chem. 283, 27200-27207
16. Lateef, S. S., Gupta, S., Jayathilaka, L. P., Krishnanchettiar, S., Huang, J. S., and Lee, B. S. (2007) An improved protocol for coupling synthetic peptides to carrier proteins for antibody production using DMF to solubilize peptides. J. Biomol. Tech. 18, 173-176
17. Clement, H. W., Vazquez, J. F., Sommer, O., Heiser, P., Morawietz, H., Hopt, U., Schulz, E., and von Dobschütz, E. (2010) Lipopolysaccharideinduced radical formation in the striatum is abolished in Nox2 gp91phoxdeficient mice. J. Neural. Transm. 117, 13-22
18. Garbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M. A., Jones, S. A., Rose-John, S., and Scheller, J. (2014) The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485-1494
19. Garbers, C., Thaiss, W., Jones, G. W., Waetzig, G. H., Lorenzen, I., Guilhot, F., Lissilaa, R., Ferlin, W. G., Grötzinger, J., Jones, S. A., Rose-John, S., and Scheller, J. (2011) Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 286, 42959-42970
20. Usón, J., Balsa, A., Pascual-Salcedo, D., Cabezas, J. A., Gonzalez-Tarrio, J. M., Martín-Mola, E., and Fontan, G. (1997) Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J. Rheumatol. 24, 2069-2075
21. Keul, R., Heinrich, P. C., Müller-newen, G., Muller, K., and Woo, P. (1998) A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10, 729-734
22. Robak, T., Gladalska, A., Stepień, H., and Robak, E. (1998) Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7, 347-353
23. Jones, S. A., Richards, P. J., Scheller, J., and Rose-John, S. (2005) IL-6 transsignaling: the in vivo consequences. J. Interferon Cytokine Res. 25, 241-253
24. Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., Strand, D., Czaja, J., Schlaak, J. F., Lehr, H. A., Autschbach, F., Schürmann, G., Nishimoto, N., Yoshizaki, K., Ito, H., Kishimoto, T., Galle, P. R., Rose-John, S., and Neurath, M. F. (2000) Blockade of interleukin 6 trans signaling suppresses Tcell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588
25. Tenhumberg, S., Schuster, B., Zhu, L., Kovaleva, M., Scheller, J., Kallen, K. J., and Rose-John, S. (2006) gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem. Biophys. Res. Commun. 346, 649-657
26. Lemmon, M. A., and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134
27. Shawver, L. K., Slamon, D., and Ullrich, A. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123